High sensitive C-reactive protein in primary prevention;Valutazione della proteina C reattiva ad elevata sensibilità in prevenzione primaria

Giornale Italiano di Cardiologia

Volumn 8, Issue 6, 2007, Pages 327-334

  Corrado, Egle ^a   Novo, Salvatore ^a  

^a Dipartimento di Medicina Interna Malattie Cardiovascolari e Nefrourologiche   (Italy)

Author keywords

Atherosclerosis; Inflammation; Primary prevention

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; CAPTOPRIL; CHOLESTEROL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FIBRIC ACID DERIVATIVE; FOSINOPRIL; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; IRBESARTAN; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; OLMESARTAN; PENTRAXIN; PIOGLITAZONE; PLACEBO; PRAVASTATIN; RAMIPRIL; ROSIGLITAZONE; TELMISARTAN; UNINDEXED DRUG; VALSARTAN; BIOLOGICAL MARKER;

AGE; ARTERY DISEASE; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIABETES MELLITUS; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; HEART INFARCTION; HUMAN; INCIDENCE; INFLAMMATION; INNATE IMMUNITY; LIPID ANALYSIS; METABOLIC SYNDROME X; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIMARY PREVENTION; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCORING SYSTEM; SECONDARY PREVENTION; SENSITIVITY ANALYSIS; SMOKING; SUDDEN DEATH; BLOOD; METABOLISM; REVIEW;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION; METABOLIC SYNDROME X; PRIMARY PREVENTION;

EID: 34548022810     PISSN: 18276806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115-26.
2. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105:1135-43.
3. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363-9.
4. Pearson TA, Mensah GA, Alexander RW, et al, for the Centers for Disease Control and Prevention, and the American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
5. Ridker PM, Cushman M, Stampfer JS, Tracy RE Hennekens C. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.
6. Hashimoto H, Kitagawa K, Hougaku H, et al. C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis. Circulation 2001; 104: 63-7.
7. Coppola G, Corrado E, Muratori I, et al. Increased levels of C-reactive protein and fibrinogen influence the risk of vascular events in patients with NIDDM. Int J Cardiol 2006; 106: 16-20.
8. Corrado E, Rizzo M, Tantillo R, et al. Markers of inflammation and infection influence the outcome of patients with baseline asymptomatic carotid lesions: a 5-years follow-up. Stroke 2006; 37: 482-6.
9. Ridker PM, Glynn JG, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97: 2007-11.
10. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98:731-3.
11. Danesh J, Whincup R Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000; 321: 199-204.
12. Koenig W, Sund M, Frohlich HG, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-42.
13. Koenig W, Lowel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham score: implications for future risk assessment. Results from a large cohort study in southern Germany. Circulation 2004; 109: 1349-53.
14. Albert MA, Danielson E, Rifai N, Ridker PM, for the PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE). A randomized trial and cohort study. JAMA 2001; 286: 64-70.
15. Ridker PM, Rifai N, Clearfield M, et al, for the Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959-65.
16. Prasad K. C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev 2006; 24: 33-50.
17. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
18. Mendall MA, Strachan DE Butland BK, et al. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J 2000; 21: 1584-90.
19. Harris TB, Ferrucci L, Tracy RE et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999; 106: 506-12.
20. Sakkinen P, Abbott RD, Curb JD, Rodriguez BL, Yano K, Tracy RP. C-reactive protein and myocardial infarction. J Clin Epidemiol 2002; 55: 445-51.
21. Novo G, Corrado E, Muratori I, et al. Markers of inflammation and prevalence of vascular disease in patients with metabolic syndrome. Int Angiol 2005; 24 (Suppl 1-3): 21.
22. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143-421.
23. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-7.
24. Frohlich M, Imhof A, Berg G, et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 2000; 23: 1835-9.